4.7 Article

Nestin+ Mesenchymal Precursors Generate Distinct Spleen Stromal Cell Subsets and Have Immunomodulatory Function

Journal

Publisher

MDPI
DOI: 10.3390/ijms231911819

Keywords

mesenchymal stromal cells; spleen; Nestin; immunoregulation; inflammatory bowel diseases

Funding

  1. National Key Research and Development Program of China, Stem Cell and Translational Research [2018YFA0107200, 2019YFA0110303, 2021YFA1100600]
  2. National Natural Science Foundation of China [32130046, 81730005, 81900075, 82170540, 81970109]
  3. Natural Science Foundation of Guangdong Province [2018A0303130305, 2021A1515011759, 2022A1515012452]
  4. Key Research and Development Program of Guangdong Province [2019B020234001, 2019B020236002, 2019B020235002]
  5. Key Scientific and Technological Program of Guangzhou City [201803040011]
  6. Pioneering talents project of Guangzhou Development Zone [2017-L163]
  7. Pearl River S&T Nova Program of Guangzhou [201906010095]
  8. Sanming Project of Medicine in Shenzhen nanshan [SZSM202103012]

Ask authors/readers for more resources

This study found that Nes-GFP(+) cells derived from the spleen have stronger immunomodulatory ability and therapeutic potential compared to those derived from bone marrow. These spleen-derived cells also demonstrated the ability to establish ectopic lymphoid-like structures.
Mesenchymal stromal cells (MSCs) are known to be widespread in many tissues and possess a broad spectrum of immunoregulatory properties. They have been used in the treatment of a variety of inflammatory diseases; however, the therapeutic effects are still inconsistent owing to their heterogeneity. Spleen stromal cells have evolved to regulate the immune response at many levels as they are bathed in a complex inflammatory milieu during infection. Therefore, it is unknown whether they have stronger immunomodulatory effects than their counterparts derived from other tissues. Here, using a transgenic mouse model expressing GFP driven by the Nestin (Nes) promoter, Nes-GFP(+) cells from bone marrow and spleen were collected. Artificial lymphoid reconstruction in vivo was performed. Cell phenotype, inhibition of T cell inflammatory cytokines, and in vivo therapeutic effects were assessed. We observed Nes-GFP(+) cells colocalized with splenic stromal cells and further demonstrated that these Nes-GFP(+) cells had the ability to establish ectopic lymphoid-like structures in vivo. Moreover, we showed that the Nes-GFP(+) cells possessed the characteristics of MSCs. Spleen-derived Nes-GFP(+) cells exhibited greater immunomodulatory ability in vitro and more remarkable therapeutic efficacy in inflammatory diseases, especially inflammatory bowel disease (IBD) than bone marrow-derived Nes-GFP(+) cells. Overall, our data showed that Nes-GFP(+) cells contributed to subsets of spleen stromal populations and possessed the biological characteristics of MSCs with a stronger immunoregulatory function and therapeutic potential than bone marrow-derived Nes-GFP(+) cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available